Press Releases

Press Releases

June 24, 2021
4D-110: Initial clinical safety data at both of the two dose levels in the Phase 1 clinical trial indicate that 4D-110 was well-tolerated and did not result in any dose-limiting toxicity (n=6; all patients followed between one and nine months) 4D-125: Initial clinical safety data at both of the two